Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is Faster Better? Senators Question Surrogate Endpoints, Fast Track Status

Executive Summary

Several U.S. senators are using congressional inquiry mechanisms to challenge the fundamental underpinnings of rapid FDA drug review

You may also be interested in...



Hypertensives May Get Class Outcome Labels; Industry Wary Of Broad Efficacy

Two major drug companies with significant hypertension profiles are welcoming the proposed inclusion of class-wide cardiovascular outcomes data in antihypertensive drug labeling - in contrast to other firms that commented on the FDA draft guidance

Hypertensives May Get Class Outcome Labels; Industry Wary Of Broad Efficacy

Two major drug companies with significant hypertension profiles are welcoming the proposed inclusion of class-wide cardiovascular outcomes data in antihypertensive drug labeling - in contrast to other firms that commented on the FDA draft guidance

FDA Chief Scientist Torti’s Plan For First 100 Days Centers On Excellence

FDA's newly appointed Chief Scientific Officer Frank Torti will focus on collaborations with industry and academia in order to boost the agency's scientific expertise and augment scarce resources, he said at a May 30 Science Board Meeting

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS049382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel